Research of cholinergic function in autism has led to clinical trials examining efficacy of cholinergic enhancement and/or acetylcholinesterase inhibitors—more commonly used in Alzheimer’s disease—to address social and cognitive aspects of autistic behaviors (Bentley et al., 2003; Hertzman, 2003; Nicolson et al., 2006; Ghaleiha et al., 2014; Karvat and Kimchi, 2014; Rossignol and Frye, 2014; Eissa et al., 2018). Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.